ArticleScientific reports2025
Deciphering the prognostic significance of WDR77 in gliomas: a comprehensive analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Deciphering Site-Specific Regulatory Networks of the Kinesin Protein KIF21A Through Integrative Phosphoproteomic Analysis.International journal of molecular sciences · 2026Article
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
- Decoding Multi-Omics Signatures in Lower-Grade Glioma Using Protein-Protein Interaction-Informed Graph Attention Networks and Ensemble Learning.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Biologically, the WDR77 gene is implicated in the occurrence and development of various clinical malignant tumors. However, its precise role in glioma remains unclear. Therefore, in this study we aimed to perform a comprehensive analysis of the biological functions of WDR77 in glioma. Transcriptome data was obtained from CGGA (mRNAseq-693, mRNAseq-325) and TCGA databases for analysis. A total of 699 glioma samples from the TCGA database were used as the training cohort, while 1018 samples from CGGA were used as the validation cohort. Our analysis revealed that WDR77 was significantly overexpressed in high-grade gliomas and mesenchymal subtype gliomas. Survival analysis indicated that elevated WDR77 gene expression was associated with poor prognostic outcomes for high-grade gliomas, particularly Glioblastoma (GBM). Gene co-expression analysis demonstrated a high correlation between WDR77 and glioma cell cycle, metabolism, and immune processes. Overall, we identified WDR77 as a new biomarker closely associated with the malignant phenotype and poor prognostic outcomes for glioma, playing an important role in regulating the cell cycle and immune processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.